PubRank

M Maral Mouradian

Author PubWeight™ 43.79‹?›

Top papers

Rank Title Journal Year PubWeight™‹?›
1 Sp1 and TAFII130 transcriptional activity disrupted in early Huntington's disease. Science 2002 4.72
2 Repression of alpha-synuclein expression and toxicity by microRNA-7. Proc Natl Acad Sci U S A 2009 2.61
3 Aggresomes formed by alpha-synuclein and synphilin-1 are cytoprotective. J Biol Chem 2003 2.42
4 Interaction between mutant ataxin-1 and PQBP-1 affects transcription and cell death. Neuron 2002 1.95
5 Interaction of DJ-1 with Daxx inhibits apoptosis signal-regulating kinase 1 activity and cell death. Proc Natl Acad Sci U S A 2005 1.91
6 The role of oxidative stress in Parkinson's disease. J Parkinsons Dis 2013 1.86
7 Mitochondrial localization of DJ-1 leads to enhanced neuroprotection. J Neurosci Res 2009 1.68
8 Tissue transglutaminase-induced aggregation of alpha-synuclein: Implications for Lewy body formation in Parkinson's disease and dementia with Lewy bodies. Proc Natl Acad Sci U S A 2003 1.40
9 MicroRNAs in neurodegenerative diseases and their therapeutic potential. Pharmacol Ther 2011 1.37
10 Parkin accumulation in aggresomes due to proteasome impairment. J Biol Chem 2002 1.30
11 Human alpha-synuclein over-expression increases intracellular reactive oxygen species levels and susceptibility to dopamine. Neurosci Lett 2002 1.23
12 DJ-1 induces thioredoxin 1 expression through the Nrf2 pathway. Hum Mol Genet 2012 1.22
13 Enhanced phosphatase activity attenuates α-synucleinopathy in a mouse model. J Neurosci 2011 1.20
14 DJ-1 protects against oxidative damage by regulating the thioredoxin/ASK1 complex. Neurosci Res 2010 1.10
15 Casein kinase II-mediated phosphorylation regulates alpha-synuclein/synphilin-1 interaction and inclusion body formation. J Biol Chem 2003 1.10
16 Striatal overexpression of DeltaFosB reproduces chronic levodopa-induced involuntary movements. J Neurosci 2010 0.97
17 Neurodegeneration and neuroprotection in multiple sclerosis and other neurodegenerative diseases. J Neuroimmunol 2006 0.96
18 Transglutaminase 2: biology, relevance to neurodegenerative diseases and therapeutic implications. Pharmacol Ther 2011 0.91
19 Neuroprotective and anti-inflammatory properties of a coffee component in the MPTP model of Parkinson's disease. Neurotherapeutics 2013 0.90
20 α-Synuclein phosphorylation as a therapeutic target in Parkinson's disease. Rev Neurosci 2012 0.88
21 Apoptosis signal-regulating kinase 1 mediates MPTP toxicity and regulates glial activation. PLoS One 2012 0.88
22 Localization of CKII beta subunits in Lewy bodies of Parkinson's disease. J Neurol Sci 2007 0.87
23 Proteasome inhibition induces α-synuclein SUMOylation and aggregate formation. J Neurol Sci 2011 0.85
24 Human Polycomb protein 2 promotes α-synuclein aggregate formation through covalent SUMOylation. Brain Res 2011 0.84
25 MicroRNAs in neurodegenerative disorders. Cell Cycle 2010 0.84
26 Perampanel, an AMPA antagonist, found to have no benefit in reducing "off" time in Parkinson's disease. Mov Disord 2011 0.83
27 Synphilin-1 degradation by the ubiquitin-proteasome pathway and effects on cell survival. J Neurochem 2002 0.83
28 IFN-beta gene transfer into the central nervous system using bone marrow cells as a delivery system. J Interferon Cytokine Res 2002 0.82
29 Advances in gene therapy for movement disorders. Neurotherapeutics 2008 0.79
30 Alpha-synuclein in Parkinson's disease: light from two new angles. Ann Neurol 2004 0.78
31 Developmental expression of the zinc finger transcription factor DRRF (dopamine receptor regulating factor). Mech Dev 2002 0.78
32 Targeting phosphatases as the next generation of disease modifying therapeutics for Parkinson's disease. Neurochem Int 2012 0.78
33 Activation of the GDNF-inducible transcription factor (GIF) gene promoter by glucocorticoid and progesterone. J Steroid Biochem Mol Biol 2009 0.78
34 Transcriptional auto-regulation of the dopamine receptor regulating factor (DRRF) gene. Mol Cell Endocrinol 2008 0.76
35 Delivery of transgenically modified adult bone marrow cells to the rodent central nervous system. Expert Opin Biol Ther 2004 0.76
36 Should levodopa be infused into the duodenum? Neurology 2005 0.75
37 Predicting the development of levodopa-induced dyskinesias: a presynaptic mechanism? Neurology 2014 0.75
38 Genomic organization and promoter characterization of the murine dopamine receptor regulating factor (DRRF) gene. Gene 2003 0.75
39 Complications of a trophic xenotransplant approach in parkinsonian monkeys. Prog Neuropsychopharmacol Biol Psychiatry 2003 0.75